Cannabis for Endometriosis in Australia — Pain Relief, Research & How to Access (2026)

Endometriosis affects approximately 1 in 9 Australian women — around 830,000 people. It is a chronic inflammatory condition in which tissue similar to the uterine lining grows outside the uterus, on the ovaries, fallopian tubes, bowel, bladder and pelvic lining. The result is severe cyclic and non-cyclic pelvic pain, painful periods (dysmenorrhoea), pain during sex (dyspareunia), bowel and bladder symptoms, fatigue and, in many cases, infertility.

Despite its prevalence, endometriosis takes an average of 6.5 years to diagnose in Australia — a delay that causes immense suffering and economic cost. Treatment options remain limited: hormonal suppression (the pill, Mirena, GnRH agonists), surgery, and pain management with NSAIDs and opioids. Many patients cycle through these options without achieving adequate relief.

Cannabis is now one of the most widely self-reported pain management strategies among Australians with endometriosis, and medicinal cannabis prescriptions for endometriosis are increasingly common. A landmark 2021 Australian survey found that 56% of women with endometriosis who used cannabis reported significant relief from menstrual pain and cramps.

This guide covers what the research actually shows, why cannabis may be uniquely suited to endometriosis’s pain mechanisms, and how to access legal treatment in Australia.

Why endometriosis may respond particularly well to cannabis

The biology of endometriosis and the biology of the endocannabinoid system (ECS) intersect in several important ways — suggesting that cannabis may be more than a general pain reliever for this condition.

ECS expression in endometriotic tissue: Research published in Molecular Human Reproduction found that endometriotic lesions have significantly lower CB1 receptor expression than normal endometrial tissue. This relative CB1 deficiency may explain why these lesions survive and proliferate — the ECS normally signals cell death (apoptosis) and suppresses inflammation, functions that are impaired in tissue with reduced CB1 expression.

Neurogenesis in endometriotic lesions: Endometriotic lesions develop their own nerve supply, which drives the chronic, often excruciating pain. CB1 receptors in these nerves regulate pain signalling; cannabis may modulate this through both central and peripheral mechanisms.

Prostaglandin and inflammation: Endometriosis is an inflammatory condition; prostaglandins are key mediators of both the tissue growth and the severe menstrual pain (dysmenorrhoea). CBD and THC both have anti-inflammatory properties that may reduce prostaglandin-driven pain — overlapping with the mechanism of ibuprofen and naproxen, but through different pathways that may be additive.

Central sensitisation: Like fibromyalgia, endometriosis is associated with central sensitisation — the central nervous system becomes hypersensitised to pain, amplifying signals beyond their peripheral source. This explains why endo pain often persists even after surgery removes visible lesions, and why cannabis’s central pain-modulating effects may be particularly relevant.

What the Australian research shows

The most important dataset comes from Australian women specifically.

2021 Human Reproduction Survey (Australia): This Australian study of 484 women with endometriosis found that:

• 56% of respondents used cannabis to manage endometriosis symptoms
• Among cannabis users, menstrual pain and cramping were the symptoms most relieved (reported by 64% of users)
• 61% reported cannabis reduced their use of other pain medications, including opioids and NSAIDs
• 52% reported cannabis improved sleep quality
• Side effects were generally mild; cognitive impairment while using was the most commonly reported concern

2020 Journal of Obstetrics and Gynaecology systematic review: Examined cannabis use for chronic pelvic pain more broadly. Found consistent self-reported pain reduction across included studies, with better effect for cyclic/menstrual pain than for constant pelvic pain.

What we lack: Placebo-controlled RCTs specifically for endometriosis. The existing data is survey-based and subject to selection bias. However, the magnitude and consistency of self-reported benefit, combined with the biological plausibility of cannabis-ECS interaction in endometriosis, makes the evidence base meaningfully stronger than in many conditions.

Symptoms cannabis can help — and those it may not

Symptom	Cannabis evidence	Best approach
Dysmenorrhoea (period pain)	Good — consistent self-report data	THC or balanced oil before/during period
Pelvic pain (cyclic)	Good	THC:CBD balanced product
Pelvic pain (constant)	Moderate	CBD + low THC consistently dosed
Dyspareunia (pain during sex)	Moderate; topical approaches also relevant	CBD topical vulvovaginal; systemic CBD:THC
Bloating and bowel symptoms	Moderate — via ECS in gut	Low-dose oral CBD
Fatigue	Moderate — secondary to sleep improvement	Evening THC addressing sleep; daytime CBD for energy
Anxiety and mood	Good	CBD-dominant daytime dosing
Sleep	Good	Evening balanced or THC oil
Reducing opioid/NSAID use	Consistent self-report across studies	CBD + THC combination
Fertility (infertility due to endo)	No evidence — does not treat lesions	Not applicable

Products and strategies for endometriosis

Period pain management (acute, cyclical)

Best approach: THC-containing oil or a balanced THC:CBD oil, started 1–2 days before the expected onset of menstruation and maintained through the most symptomatic days.

Unlike continuous daily dosing, some patients with primarily cyclical pain use cannabis as an acute intervention — stepping up dosing in the days around menstruation and reducing between cycles. This “pulsed” approach reduces cumulative THC exposure and associated tolerance development.

Starting dose for cyclical use: 2.5–5mg THC + equivalent or double CBD, 2–3 times daily during the symptomatic period.

Chronic pelvic pain (non-cyclic)

For the significant proportion of endometriosis patients with persistent, non-cyclic pelvic pain, consistent daily dosing is more effective than as-needed use.

Daytime: CBD-dominant oil (50–100mg CBD, twice daily) maintains baseline anti-inflammatory and pain-modulating effects without impairing daytime function.

Evening: Balanced THC:CBD oil (1:1 or 2:1 CBD:THC) for overnight pain management and sleep quality. Starting THC dose: 2.5–5mg.

Dyspareunia (pain during sex)

Topical CBD products applied to the vulval area and vaginal opening before sex have gained significant interest in endometriosis communities — and there is physiological plausibility: CB1 receptors are expressed throughout the vaginal mucosa and uterine tissue, and topical CBD may reduce local inflammation and sensitisation.

While formal clinical trial data for vulvovaginal CBD topicals is limited, anecdotal and survey reports are consistent. Look for CBD topicals specifically formulated for intimate use — these use water-soluble or oil-based CBD formulations compatible with mucous membranes. Note that oil-based CBD products are incompatible with latex condoms.

Systemic CBD (oral) in the hours before anticipated sex may complement topical application by addressing the central anxiety and pain anticipation that compounds dyspareunia.

Bowel symptoms

Endometriosis affecting the bowel — bowel endo causes pain with defecation, bloating and altered bowel habits. The gut has its own dense endocannabinoid signalling system (the enteric nervous system). Low-dose oral CBD has anti-inflammatory effects in the gut and may reduce bowel endo-related pain. Read how cannabis affects gut symptoms in our pain guide.

Managing the hormonal treatment side effects

Many endometriosis patients are on hormonal treatments (GnRH agonists like Zoladex, Lucrin) that cause significant side effects including hot flushes, mood disturbance, insomnia and joint pain. These are legitimate additional indications for medicinal cannabis alongside the endometriosis itself, and can be included in your consultation with a medicinal cannabis prescriber.

Important considerations for people with endometriosis

Hormonal interactions: Available evidence does not show significant clinically meaningful interaction between cannabinoids and most hormonal endometriosis treatments (GnRH agonists, combined oral contraceptive pill, levonorgestrel IUD). The liver enzyme interactions that matter for pharmaceutical drugs are less established for hormonal medications. Disclose cannabis use to your gynaecologist.

Fertility considerations: There is limited evidence suggesting high-dose THC may affect ovarian reserve and embryo development in preclinical models. The clinical significance in humans at therapeutic doses is uncertain. If you are actively trying to conceive or undergoing IVF, discuss cannabis use with your fertility specialist before starting or continuing. CBD-only products are generally considered lower risk in this context.

Pregnancy: Cannabis (including CBD) is contraindicated during pregnancy. If there is any possibility you may be pregnant, do not use medicinal cannabis. Discuss management of endometriosis pain with your obstetrician if symptoms occur during pregnancy.

How to get a medicinal cannabis prescription for endometriosis in Australia

Endometriosis is an accepted indication for medicinal cannabis prescription under the TGA’s SAS-B framework. Chronic pelvic pain — the primary symptom — is one of the most commonly approved pain indications.

Step 1: Speak to your GP or gynaecologist Your GP can prescribe medicinal cannabis under SAS-B without specialist referral. Your gynaecologist may be able to prescribe directly — increasing numbers of Australian gynaecologists are now comfortable with cannabis prescribing for chronic pelvic pain.

Step 2: Telehealth platforms If you prefer a dedicated cannabis consultation, Alternaleaf, Polln and Leafio offer appointments typically within days. Bring your endometriosis diagnosis (surgical confirmation if available), current medications and hormone treatments, and a brief symptom diary including pain scores and menstrual cycle tracking.

Step 3: What to expect Your prescriber will review your endometriosis history, current treatments, pain severity and pattern, and any existing medications. They will recommend a starting product suited to your pain pattern — cyclical versus constant — and arrange home delivery of medication within 2–7 business days.

Cost: $100–250/month for most endometriosis cannabis regimens. Not PBS-listed. Some private health insurance policies offer partial reimbursement.

Endometriosis Australia provides resources and peer support for navigating medicinal cannabis as part of endometriosis management: endometriosisaustralia.org

Frequently asked questions

Is cannabis legal for endometriosis in Australia? Yes, with a prescription. Chronic pelvic pain and period pain are accepted indications for medicinal cannabis prescriptions under the TGA’s SAS-B framework. Any GP can prescribe. Endometriosis Australia maintains resources on accessing medicinal cannabis.

Can cannabis shrink endometriosis lesions? There is no clinical evidence that cannabis reduces or eliminates endometriosis lesions in humans. Preclinical data suggests cannabinoids can promote apoptosis (cell death) in endometriotic cell cultures, but this has not translated to clinical treatment efficacy. Cannabis manages the pain and symptoms of endometriosis — it does not treat the underlying disease. Surgery and hormonal suppression remain the primary treatments for lesion reduction.

What is the best cannabis product for period pain? For dysmenorrhoea, THC-containing products are most effective — specifically because THC’s central pain-modulating effects and muscle-relaxant properties directly address the cramping and pain amplification of severe period pain. A balanced THC:CBD oil (1:1 or 2:1 CBD:THC) taken the day before and during menstruation is the most common approach. CBD-only products provide some benefit for mild-to-moderate period pain but are less effective than THC-containing products for severe dysmenorrhoea.

Can CBD topicals help with endo pain? For localised vulvovaginal pain and dyspareunia, CBD topicals specifically formulated for intimate use may provide meaningful local relief. The evidence is primarily from patient surveys rather than clinical trials but is consistent. Systemic CBD (oral) complements topical use by addressing central pain sensitisation.

Will cannabis affect my fertility treatment? High-dose THC has preclinical evidence of effects on ovarian reserve and embryo development. If you are undergoing IVF or actively trying to conceive, discuss cannabis use with your fertility specialist. CBD-only products are generally considered lower risk but should still be disclosed to your fertility team.

How quickly does cannabis work for endometriosis pain? Vaporised THC works within 5–15 minutes for acute pain relief. Oral oils take 30–90 minutes to reach peak effect. For ongoing pain management, consistent daily dosing with oral products provides more stable relief than as-needed use. The full anti-inflammatory benefit of regular CBD use may take 3–4 weeks to become apparent.

Can I take cannabis with naproxen (Naprogesic) or ibuprofen? Yes. Cannabis and NSAIDs can be used together — they work through different pain mechanisms and there is no significant pharmacokinetic interaction. Many endometriosis patients find that cannabis reduces the amount of NSAIDs needed for adequate pain control.

Does cannabis help with the emotional impact of living with endometriosis? Yes. The chronic nature of endometriosis, combined with diagnostic delays and inadequate treatment, causes significant anxiety and depression in many patients. CBD’s anxiolytic and antidepressant effects (via 5-HT1A agonism and neurogenesis support) directly address these. Addressing the emotional dimensions of endometriosis often reduces the pain experience as well, since anxiety amplifies perceived pain intensity.